{Reference Type}: Journal Article
{Title}: Applicability and validation of different prognostic scores in allogeneic hematopoietic cell transplant (HCT) in the post-transplant cyclophosphamide era.
{Author}: Salas MQ;Rodríguez-Lobato LG;Charry P;Suárez-Lledó M;Pedraza A;Solano MT;Arcarons J;Cid J;Lozano M;Rosiñol L;Esteve J;Carreras E;Fernández-Avilés F;Martínez C;Rovira M;
{Journal}: Hematol Transfus Cell Ther
{Volume}: 0
{Issue}: 0
{Year}: 2023 Oct 12
暂无{DOI}: 10.1016/j.htct.2023.07.008
{Abstract}: We investigated the predictive capacity of six prognostic indices [Karnofsky Performance Status (KPS), Hematopoietic Cell Transplant-Specific Comorbidity Index (HCT-CI), Disease Risk Index (DRI), European Bone Marrow Transplantation (EBMT) and Revised Pre-Transplantation Assessment of Mortality (rPAM) Scores and Endothelial Activation and Stress Index (EASIX)] in 205 adults undergoing post-transplant cyclophosphamide (PTCy)-based allo-HCT. KPS, HCT-CI, DRI and EASIX grouped patients into higher and lower risk strata. KPS and EASIX maintained appropriate discrimination for OS prediction across the first 2 years after allo-HCT [receiver operating characteristic curve (area under the curve (AUC) > 55 %)]. The discriminative capacity of DRI and HCT-CI increased during the post-transplant period, with a peak of prediction at 2 years (AUC of 61.1 % and 61.8 %). The maximum rPAM discriminative capacity was at 1 year (1-year AUC of 58.2 %). The predictive capacity of the EBMT score was not demonstrated. This study validates the discrimination capacity for OS prediction of KPS, HCT-CI, DRI and EASIX in PTCy-based allo-HCT.